We’re excited to share that PharmaEssentia will be presenting at #JPM2025 on Thursday, January 16th at 1:45PM PT. A live webcast of the presentation will be available through the News section of our website, and replays will be archived for at least 30 days: https://lnkd.in/gDNabPNn Read more in the latest press release: https://lnkd.in/gf2AaKjD
PharmaEssentia
Biotechnology Research
Burlington, MA 11,572 followers
Better Science, Better Lives.
About us
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan, leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology, and immunology. Founded in 2003, PharmaEssentia is now expanding its global presence with operations in the U.S., Japan, China and Korea.
- Website
-
https://us.pharmaessentia.com
External link for PharmaEssentia
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Burlington, MA
- Type
- Public Company
- Founded
- 2003
- Specialties
- Biologics, Oncology, Rare Disease, Orphan Drugs, Orphan Disease, Drug Development, Pharmaceuticals, and Hematology
Locations
Employees at PharmaEssentia
Updates
-
Know the facts about polycythemia vera (PV). PV is a chronic blood cancer that affects approximately 160,000 people in the U.S. Learn more about our focus on providing potential therapeutic solutions for patients with #MPNs: https://lnkd.in/gMqBgEXg
-
At the 66th American Society of Hematology Annual Meeting, PharmaEssentia showcased 9 new studies highlighting our commitment to the treatment of patients with chronic and life-threatening myeloproliferative neoplasms(#MPNs). These findings deepen our understanding of the role of our treatment in chronic MPNs and reaffirm our commitment to improving patient care in #hematology. Learn more about how we’re developing novel solutions with pioneering science: https://lnkd.in/etfH6qxp #PolycythemiaVera #EssentialThrombocythemia
-
-
We’re excited to share our latest research and connect with the best and brightest in #hematology at #ASH24! Visit our interactive booth #3229 and enter the Marrowverse, where you can learn more about how we are working diligently to help improve outcomes and care for #PolycythemiaVera (PV) patients.
-
-
The PharmaEssentia team was proud to support The American Society of Hematology Foundation’s Annual Run/Walk at #ASH24! Thanks to the team who showed up bright and early in support of #hematology research.
-
-
Today, we announced the appointment of Joe Horvat as Global Chief Commerical Officer at PharmaEssentia. In his new role, Joe will lead global resource allocation to align commercial strategies and drive performance, ensuring the highest level of performance across our global operations. Learn more: https://lnkd.in/e8ZCTGMn
-
-
Join us in congratulating Chief Scientific Officer Lih-Ling Lin, Ph.D. on being named one of Women We Admire’s Top 25 Chief Scientific Officers of 2024! Dr. Lin joined the PharmaEssentia team in 2022 and has since been an integral part of our growth and leading our global research and development. Congratulations on this well-deserved honor. We are so thankful to have you on our team! Read more: https://lnkd.in/gfB6rDfB
-
-
Today, we announced that nine new abstracts will be presented during the 66th American Society of Hematology Annual Meeting and Exposition in San Diego, CA. Learn more: https://lnkd.in/ept_Kj4B #ASH24 #MPNs
-
-
PharmaEssentia started by bringing together leading scientists from the U.S., Taiwan, and beyond to unlock the full potential of interferon-based therapies, specifically for diseases such as polycythemia vera. With a focus on improving the lives of those impacted by this rare condition, we are continuously evolving our approach to treatment under the leadership of Dr. Ko-Chung Lin. Read more about our story: https://lnkd.in/dUfQvRry
-